Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL9935686

C=CCS(=O)(=O)O.CCCC[N+](CCCC)(CCCC)CCCC

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 3/20 0.46
SLC22A2 O15244 1/20 0.41
TSHR P16473 3/20 0.38
ALDH1A1 P00352 2/20 0.38
TP53 P04637 2/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
DNM1 Q05193 4/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9935791 0.93 SLC22A1 (0.38) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL9934681 0.93 DNM1 (0.42) SLC22A1SLC22A2TSHRALDH1A1TP53
Pentadecane SCHEMBL27822400 0.88 TSHR (0.46) TSHRALDH1A1TP53ZDHHC20ZDHHC2
Tributylmethylammonium SCHEMBL9936102 0.87 ENPP2 (0.33) SLC22A1TSHRALDH1A1DNM1ZDHHC20
SCHEMBL9935057 0.84 DNM1 (0.52) TSHRSMN1; SMN2HSD17B10DNM1
SCHEMBL9934338 0.84 DNM1 (0.52) TSHRSMN1; SMN2HSD17B10DNM1
SCHEMBL1043210 0.82 EPHX2 (0.46) TSHRALDH1A1TP53ZDHHC20ZDHHC2
Tetrabuthylammonium SCHEMBL795551 0.82 SLC22A1 (0.52) SLC22A1SLC22A2TSHRALDH1A1TP53
Tetrabuthylammonium SCHEMBL331004 0.81 SLC22A1 (0.63) SLC22A1SLC22A2TSHRALDH1A1TP53
SCHEMBL6368044 0.81 ZDHHC20 (0.39) TSHRALDH1A1TP53ZDHHC20ZDHHC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103823331-B Photoresists comprising ionic compound 罗门哈斯电子材料有限公司 2017-05-10 CN disclosed
US-8546609-B2 Ionic liquid containing allylsulfonate anion WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-01 US disclosed
EP-2474527-A1 IONIC LIQUID CONTAINING ALLYLSULFONATE ANION Wako Pure Chemical Industries, Ltd. (JP) 2012-07-11 EP disclosed
US-20120157680-A1 IONIC LIQUID CONTAINING ALLYLSULFONATE ANION WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157680-A1 IONIC LIQUID CONTAINING ALLYLSULFONATE ANION ATXN2L, ARL1, INPPL1 SLC22A1 1635/4885SLC22A2 1792/4885TSHR 2384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.